IBM Watson Health (NYSE:IBM) and the US Dept. of Veterans Affairs said today they extended their partnership using artificial intelligence to help interpret oncological data in the treatment of veteran patients. The partnership, originally signed between the two groups two years ago as part of the National Cancer Moonshot Initiative, will now be extended through to […]
RenovoRx sets its sights on localized treatment of pancreatic cancer
People living with pancreatic cancer find themselves facing devastating odds – the five-year survival rate is in the single digits, according to the American Cancer Rate. Pursuing treatment often means dealing with the side effects of systemic chemotherapy, including hair loss, fatigue and neuropathy. Shaun Bagai and his team at RenovoRx think that their catheter could help […]
Dysis Medical raises $25m
Dysis Medical said yesterday it raised $25 million (GBP £18 million) in a new round to help support its Dysis colposcope used for cervical cancer screenings. The Dysis colposcope uses both optical imaging and software to scan the cervix to improve cervical cancer screening procedures, the company said. Funds in the round will help support […]
IsoRay wins FDA nod for GammaTile brain tumor treatment
IsoRay (NYSE:ISR) said today it won FDA 510(k) clearance for its GammaTile brachytherapy technology designed for treating recurrent brain tumors. The Richland, Wash.-based company’s GammaTile is a radiation system using Cesium-131 radiation seeds embedded in a collagen ’tile’ which is designed to be placed in surgical margins at the time of surgery. IsoRay said it had […]
Precision Therapeutics finalizes Helomics buy, completes pivot to personalized medicine
Precision Therapeutics (NSDQ:AIPT) said yesterday it inked a definitive merger agreement with Helomics, completing the company’s plan to pivot towards artificial-intelligence powered personalized medicine. Minneapolis-based Precision Therapeutics inked a deal to acquire the remaining 75% equity stake in Helomics in April, after having purchased preferred stock in the company convertible into a 20% stake in January and converting […]
CEL-SCI wins $2.9M in CRO legal battle
Score one for the little guy. After a four-year legal battle, immunotherapy maker CEL-SCI Corporation has won the first-ever breach-of-contract case against a contract research organization, or CRO. In a final and binding decision, an arbitrator concluded that CRO inVentiv knowingly and fraudulently misled CEL-SCI with regard to enrollment projections for a clinical trial of […]
Elekta wins CE Mark for Unity high-field MR-linac
Elekta (STO:EKTA B) said today it won CE Mark approval in the European Union for its Elekta Unity magnetic resonance radiation therapy system. The Stockholm-based company touted that its Unity system allows clinicians to deliver radiation doses while simultaneously visualizing the tumor and surrounding tissue through MR imaging. The system also features integrated advanced tools […]
Sirtex accepts CDH acquisition offer, moves away from Varian
In the ongoing back-and-forth to acquire Sirtex Medical (ASX:SRX), it seems that Varian Medical‘s (NYSE:VAR) $1.2 billion bid just wasn’t enough. Varian said today that it heard from Sirtex that the company’s board couldn’t turn down the $1.41 billion unsolicited offer from China’s CDH Investments. The bid from CDH Investments came in at a 20% premium on Varian’s […]
Stealthy Vergent Bioscience raises $9m for tumor-fluorescing tech
Vergent Bioscience came out of stealth mode today to reveal a nearly $9 million equity offering for the injectable molecular probe it’s developing to visualize tumors during surgery. Minneapolis-based Vergent Bioscience’s technology uses a proprietary injectable, tumor-targeting molecule that binds to tumor cells and fluoresces, president & CEO John Santini told MassDevice.com last week at the DeviceTalks […]
NanOlogy touts preclinical data for inhaled NanoPac cancer drug
NanOlogy touted results today from preclinical studies of its inhaled submicron particle formulation of paclitaxel, NanoPac. The company said animal studies have shown prolonged retention of the cancer drug in lung tissue and significant tumor regression without adverse drug-related side effects. Get the full story at our sister site, Drug Delivery Business News.
MIT researchers send drug-ferrying nanoparticles across the blood-brain barrier
Researchers at the Massachusetts Institute of Technology demonstrated in an animal study that nanoparticles shuttling two different cancer drugs could effectively cross the blood-brain barrier and target tumor cells. The team of scientists evaluated the drug combination in mice that had gliobastoma – an aggressive form of brain cancer that is notoriously hard to treat. […]
- 1
- 2
- 3
- …
- 67
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
Google+